Applied Therapeutics Inc (APLT)
4.795
+0.26
(+5.85%)
USD |
NASDAQ |
May 03, 13:34
Applied Therapeutics Cash from Investing (TTM): 13.87M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 13.87M |
September 30, 2023 | 6.967M |
June 30, 2023 | 11.99M |
March 31, 2023 | 17.52M |
December 31, 2022 | 13.17M |
September 30, 2022 | 31.88M |
June 30, 2022 | 35.38M |
March 31, 2022 | 46.63M |
December 31, 2021 | 12.43M |
September 30, 2021 | 29.07M |
Date | Value |
---|---|
June 30, 2021 | -9.694M |
March 31, 2021 | -2.43M |
December 31, 2020 | -19.47M |
September 30, 2020 | -48.04M |
June 30, 2020 | -37.67M |
March 31, 2020 | -61.72M |
December 31, 2019 | -20.01M |
September 30, 2019 | -19.88M |
June 30, 2019 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-61.72M
Minimum
Mar 2020
46.63M
Maximum
Mar 2022
--
Average
6.967M
Median
Sep 2023
Cash from Investing (TTM) Benchmarks
Sarepta Therapeutics Inc | 40.50M |
Fate Therapeutics Inc | 112.66M |
Viking Therapeutics Inc | -641.08M |
Terns Pharmaceuticals Inc | -37.99M |
Edgewise Therapeutics Inc | 102.89M |